The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sachs Associates have posted the following on Linkedin:-
Scancell is a clinical stage immunoncology company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs.
Scancell's lead asset SCIB1, a cancer vaccine being evaluated in first line unresectable metastatic melanoma and has impressive early clinical results as a monotherapy (88% DFS) and in combination with checkpoint inhibitors (85% ORR). The next data is anticipated in Q3 2024.
More Info @ https://lnkd.in/djZps36w
This is the link to the website:-
https://www.sachsforum.com/10oif-about.html
Sath Nirmalananthan and Brad Loncar, Founder, BiotechTV are among the “Confirmed Speakers and Chairs”.
Sath is one of the Panellists in the following 50 minute slot at 11.30 am:-
“Advanced Immunotherapies Panel:
Cell Therapies & Cancer Vaccines
Co-Chaired by: Kaveri Pohlman, Director, Biotechnology Equity Research, BTIG, LLC
Michael Rice, Expert Advisor, SVP, Cell & Gene Therapy, Lumanity
Panellists: Deborah Rathjen, Managing Director & CEO, Carina Biotech Limited
Niranjan Sardesai, Founder, President & CEO, Geneos Therapeutics, Inc. Polly Brown, VP, Head of Business Development, Oncology R&D, AstraZeneca
Sath Nirmalananthan, Chief Financial Officer, Scancell Holdings PLC
Upendra Marathi, CEO, 7 Hills Pharma Inc.”
Sath is a bit of an all-rounder
https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/230829-scancell-cfo-pr-final.pdf
"Sath earned a BSc in Pharmacology from King’s College,
London, UK and holds an ACA (ICAEW), Chartered Accountant qualification"
He can tell the other panellists all about SCIB1 and then tell them what the price tag is 😂
Sorry it is 11.40 am. This is the Agenda:-
https://drive.google.com/file/d/1-WeggpKG_BTfijvY1diwnYZa00rKpXoK/view
Thanks Johnny and thanks to Ray also, for the reminder about Sath's other 'arm'.
Sath is a major player at Scancell now and seems to have fullest support of the CEO. IMO, he is a very considerable asset. Now for news please!
Seeing "Panellists: Deborah Rathjen, Managing Director & CEO, Carina Biotech Limited" reminded me how company execs can abandon sinking ships and apparently easily get onboard elsewhere to start afresh, while shareholders are left with nothing.
Bioasis, BTI on Canadian Venture, was in the world of trying to transport therapeutic drugs over the BBB using a peptide developed from a natural human protein transporter (melanotransferrin, p97) ), which seemed to work well in the lab, but despite three changes of management, with "Dr DR" as we knew here on Stockhouse being the final attempt, they never managed to sign a partner to develop clinical trials, let alone commercialise it! "Dr DR" was living in Aus and had other roles, so that didn't help either.
See the 14-year downhill trip to oblivion here https://yhoo.it/3I5MwhI on Yahoo (Not available on the cleaner Stockcharts as they have already deleted the symbol it seems).
So, just a reminder there is more pain for shareholders than execs when things go wrong. This is not a comment on Scancell of course, just a weak coincidental connection to a biotech example in the world of startups.
Save... that's the risk of investing in biotechnology companies. High risk ..High reward. As long as management spend funds carefully and have a good stragic plan...then shareholders can't blame them if things don't work out. It's the risk they take for the rewards.
Scancell do appear to lookafter the funds , have strengthened management, have an excellent strategic view... and the management don't have lifestyles at shareholders expenses. I'm confident in the management of Scancell and the risk is mine . Yes, LD had options extended but that's not a big deal in my book unless they are rolled over again. We will know Q3 Q4 the results of the SCOPE trial which will be a significant event either way..so time to get out if your not confident in either the management or the science...